Cox-2 inhibitors, developed with much hype in the mid-1990s, block an enzyme called cyclooxygenase-2, in so doing shutting off a wide-reaching cascade of biochemical signals that take the form of fats called prostaglandins.

FORBES: Pharma Prophet